首页> 外国专利> Association of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory lung diseases

Association of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory lung diseases

机译：HMG-CoA还原酶抑制剂阿托伐他汀或辛伐他汀与磷酸二酯酶4抑制剂（例如罗氟司特）的关联，用于治疗炎症性肺病

页面导航

摘要
著录项
相似文献

摘要

Pharmaceutical composition comprising a pharmaceutical formulation that includes an amount of a PDE4 inhibitor, an amount of an HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable adjuvant, wherein the PDE4 inhibitor is selected from the group consisting of : ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is SIMVASTATIN or a pharmaceutically acceptable salt thereof and in which the The first quantity and the second quantity together comprise an effective amount for the preventive or curative treatment of an inflammatory lung disease.

机译：包含药物制剂的药物组合物，所述药物制剂包含一定量的PDE4抑制剂，一定量的HMG-CoA还原酶抑制剂和至少一种药学上可接受的佐剂，其中PDE4抑制剂选自：ROFLUMILAST，药学上可接受的盐ROFLUMILAST，ROFLUMILAST-N-氧化物和ROFLUMILAST-N-氧化物的药学上可接受的盐，HMG-CoA还原酶抑制剂是西伐他汀或其药学上可接受的盐，其中第一数量和第二数量共同构成有效量用于炎性肺病的预防或治疗。

著录项

公开/公告号ES2489265T3

专利类型
公开/公告日2014-09-01

原文格式PDF
申请/专利权人 TAKEDA GMBH;
展开▼

申请/专利号ES20110164518T
发明设计人 WOLLIN STEFAN-LUTZ;WOHLSEN ANDREA;BRAUN CLEMENS;MARX DEGENHARD;
展开▼

申请日2007-07-03
分类号A61K31/44;A61K31/22;A61K31/277;A61K31/343;A61K31/352;A61K31/366;A61K31/40;A61K31/405;A61K31/437;A61K31/4439;A61K31/453;A61K31/502;A61K31/505;A61K45/06;A61P11;
国家 ES
入库时间 2022-08-21 15:55:00

相似文献

专利
外文文献
中文文献